Forodesine

chembox new
ImageFile=Forodesine.pngImageSize=200px
IUPACName=7- [(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl] -1,5-dihydropyrrolo [2,3-e] pyrimidin-4-one
OtherNames=
Section1=Chembox Identifiers
CASNo=
PubChem=444499
SMILES=C1=C(C2=C(N1)C(=O)N=CN2)C3C(C(C(N3)CO)O)O
Section2=Chembox Properties
Formula=C₁₁H₁₄N₄O₄
MolarMass=266.25326
Appearance=
Density=
MeltingPt=
BoilingPt=
Solubility=
Section3=Chembox Hazards
MainHazards=
FlashPt=
Autoignition=

Forodesine (INN; also known as Immucillin H) is a transition-state analog inhibitor of purine nucleoside phosphorylasecite journal |author=Kicska GA, Long L, Hörig H, "et al" |title=Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=98 |issue=8 |pages=4593–8 |year=2001 |month=April |pmid=11287638 |pmc=31879 |doi=10.1073/pnas.071050798 |url=] under development for the treatment of relapsed B-cell chronic lymphocytic leukemia

Forodesine is being developed by BioCryst. As of 2008, it is currently in phase II clinical trials. [cite web |url=http://www.clinicaltrials.gov/ct2/results?term=Forodesine&flds=Xabce |title=Complete list of clinical trials for forodesine (BCX-1777) (ClinicalTrials.gov) |format= |work= |accessdate=2008-07-22]

References